Michael Fox
Pulmonary Disease · Orange, CANPI 1053389254
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $897 and has fallen 97.4% since, to $24 in 2022.
Across 116 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$420
- AstraZeneca$231
- Boehringer Ingelheim$219
- AbbVie$155
- Johnson & Johnson$132
- Vanda Pharmaceuticals Inc.$90
- plus $650 from 18 others
What the payments were for
- Food & beverage$1,897100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $420 |
| AstraZeneca | 13 | $231 |
| Boehringer Ingelheim | 15 | $219 |
| AbbVie(2 entities) | 8 | $155 |
| Johnson & Johnson | 7 | $132 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Insmed, Inc. | 5 | $90 |
| Lilly USA, LLC | 4 | $75 |
| Pfizer | 4 | $68 |
| Genentech USA, Inc. | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 3 | $56 |
| Grifols USA, LLC | 2 | $38 |
| Merck | 3 | $37 |
| Mylan Specialty L.p. | 2 | $33 |
| Mayne Pharma Commercial LLC | 2 | $31 |
| Philips North America LLC | 1 | $25 |
| Tactile Systems Technology Inc | 2 | $24 |
| Medtronic | 1 | $24 |
| Novo Nordisk | 1 | $19 |
| Novartis | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Vertiflex, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,897 in reported general payments places this provider in the 55th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Orange
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.